| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vivo |
Sultopride Hydrochloride (LIN-1418 HydroHClide) is a selective antagonist of dopamine D2 receptors. Rats treated with both sultopride hydrochloride and sulpiride showed higher levels of DOPAC and HVA in the striatum, nucleus accumbens, and medial prefrontal cortex when compared to controls. In the striatum, sulpiride hydrochloride-treated rats had higher levels of DOPAC and HVA than sulpiride-treated rats (p<0.05). In the nucleus accumbens, sulpiride hydrochloride-treated rats had higher DOPAC and HVA levels than sulpiride-treated rats (p<0.05). In rats treated with sultopride hydrochloride and sulpiride, DOPAC and HVA levels were higher in the striatum or nucleus accumbens than in the medial prefrontal cortex (p<0.05) [1].
|
|---|---|
| References |
[1]. Moriuchi K, et al. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res. 1995 Jan;20(1):95-9
|
| Additional Infomation |
A benzamide derivative that is used as an antipsychotic agent for the treatment of schizophrenia. It is also used as an antidepressive agent.
|
| Molecular Formula |
C17H27CLN2O4S
|
|---|---|
| Molecular Weight |
390.92
|
| Exact Mass |
390.138
|
| CAS # |
23694-17-9
|
| Related CAS # |
Sultopride;53583-79-2
|
| PubChem CID |
3082221
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.16g/cm3
|
| Boiling Point |
530ºC
|
| Melting Point |
181-182ºC
|
| Vapour Pressure |
2.57E-11mmHg at 25°C
|
| LogP |
3.914
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
25
|
| Complexity |
517
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(CC)=O)=CC=C2OC.Cl
|
| InChi Key |
IGOWMQPOGQYFFM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H26N2O4S.ClH/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)1H
|
| Chemical Name |
N-((1-Ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide hydrochloride
|
| Synonyms |
Sultopride Hydrochloride Sultopride HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~127.90 mM)
H2O : ~50 mg/mL (~127.90 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 140 mg/mL (358.12 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5581 mL | 12.7903 mL | 25.5807 mL | |
| 5 mM | 0.5116 mL | 2.5581 mL | 5.1161 mL | |
| 10 mM | 0.2558 mL | 1.2790 mL | 2.5581 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01498770 | COMPLETED | Drug: Asenapine Drug: Aripiprazole Drug: Quetiapine |
Bipolar Disorder | Organon and Co | 2013-04-01 | |
| NCT01323205 | COMPLETED | Drug: JNJ-40411813 Drug: JNJ-40411813 Drug: Placebo Drug: Antipsychotic medication |
Schizophrenia | Janssen Research & Development, LLC | 2011-05 | Phase 2 |
| NCT02374567 | TERMINATED | Drug: Phenobarbital Drug: Phenytoin Drug: Carbamazepine |
Anxiety Disorders Dementia Depression Psychosomatic Disorders Schizophrenia |
Hannover Medical School | 2015-01 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA